Login / Signup

Obinutuzumab in two patients suffering from immune-mediated thrombotic thrombocytopenic purpura intolerant to rituximab.

Judith RobertzMartin AndresBehrouz Mansouri TaleghaniIrene KonethIsabelle BinetJohanna A Kremer Hovinga
Published in: American journal of hematology (2019)
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • diffuse large b cell lymphoma
  • chronic lymphocytic leukemia
  • hodgkin lymphoma